Effect of Atropine on Pupil Size & Quality of Vision

Status Not yet recruiting

Clinical Trial Summary

This aims to investigated the short-term (12, 16, and 20 h) effects of 0.01% atropine (0.1 mg/ml) on pupil size and subjective quality of vision in participants with myopia. Particpants will receive 0.01% atropine one drop to both eyes before bedtime. Baseline parameters were measured before atropine application. Changes in pupil sizes, under photopic and mesopic conditions, high-order aberration, and tear meniscus height were observed over the next day (12, 16, and 20 h).

Clinical Trial Description

The utilisation of atropine drops is a common practise in order to induce pupil dilatation, impede accommodation, and decelerate the advancement of myopia. Research findings indicate that the treatment of atropine at a low concentration of 0.01% has been observed to effectively slow down the advancement of myopia, with a reduction rate ranging from 60% to 83%. The administration of a lesser dose of atropine demonstrates a decreased occurrence of undesirable effects in comparison to the administration of atropine at a high concentration of 1.0%. Nevertheless, it is crucial to acknowledge that even when present in low concentrations, atropine still exerts an influence on both pupil size and pupil responsiveness. This investigation employs a prospective cohort study design, in which a set of objective and subjective assessments will be carried out before and after the injection of 0.01% atropine for a duration of 18 hours. The main aim of this study is to determine the effects of a specific concentration of atropine on several factors, including: 1) visual acuity; 2) pupil diameter; 3) subjective perception of vision quality; and 4) intraocular pressure. The objective of this study is to examine the effects of the eye drops on ocular health and determine the degree of patient acceptance about their prospective use as a preventive measure for myopia. The researchers have a positive expectation that the administration of the drops will have minimal influence on the participants in terms of side effects. However, the outcomes of this study will provide valuable insights for children and patients in effectively managing the side effects associated with the use of atropine for myopia control. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06071260
Study type	Interventional
Source	He Eye Hospital
Contact
Status	Not yet recruiting
Phase	N/A
Start date	December 1, 2023
Completion date	December 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05919654` - Clinical Evaluation of MyoCare in Europe (CEME)	N/A
Recruiting	`NCT03402100` - Eye Drops Study for Myopia Control in Schoolchildren	N/A
Recruiting	`NCT03865160` - Low-dose Atropine for Myopia Control in Children	Phase 2/Phase 3
Recruiting	`NCT06088225` - Myopia Preventing With Distance-image Screen	N/A
Not yet recruiting	`NCT06085430` - Kubota Glass Parameter Refinement Study	N/A
Recruiting	`NCT05881655` - Slow Myopia Progression With Different Irradiance Light	N/A
Recruiting	`NCT05761379` - Clinical Study of Light Therapy to Control Myopia Progression in Children	N/A
Not yet recruiting	`NCT05760911` - Myopia Prevention Through Monitoring and Motivating Outdoor Activities With Smartwatches	N/A
Recruiting	`NCT04722874` - Repeated Low-Level Red-Light Therapy and Orthokeratology in Fast-progressing Myopia Control	N/A
Not yet recruiting	`NCT06221592` - Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses	N/A
Completed	`NCT04806763` - Myopia Control With Orthokeratology Contact Lenses in Spain	N/A
Completed	`NCT04806698` - Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia	N/A
Completed	`NCT04806711` - Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children	N/A
Recruiting	`NCT05894382` - Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control	N/A
Completed	`NCT05683535` - Adverse Events Related to Low Dose Atropine
Completed	`NCT05300321` - DIMS-myopia Progression ADN Axial Length Growth	N/A
Withdrawn	`NCT03519490` - Can Distance Center and Near Center Multifocal Contact Lenses Control Myopia Progression in Children?	N/A
Completed	`NCT05372991` - Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop	Phase 1/Phase 2
Active, not recruiting	`NCT05373693` - Myopia-control Efficacy by Peripheral Defocus Lens (PDL)	N/A
Completed	`NCT05007626` - Near Horizontal Heterophoria in Chinese Children

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Atropine on Pupil Size and Quality of Vision

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms